[Federal Register Volume 89, Number 247 (Thursday, December 26, 2024)]
[Proposed Rules]
[Pages 104908-104909]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-30362]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 172
[Docket No. FDA-2024-F-5640]
Monterey Mushrooms, LLC; Filing of Food Additive Petition
AGENCY: Food and Drug Administration, HHS.
ACTION: Notification of petition.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing
that we have filed a petition, submitted by Monterey Mushrooms, LLC,
proposing that the food additive regulations for vitamin D2
mushroom powder be amended to provide for an additional method for
producing the additive.
DATES: The food additive petition was filed on December 11, 2024.
ADDRESSES: For access to the docket to read background documents or
comments received, go to https://www.regulations.gov and insert the
[[Page 104909]]
docket number found in brackets in the heading of this document into
the ``Search'' box and follow the prompts, and/or go to the Dockets
Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Katie Overbey, Human Foods Program,
Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740,
240-402-7536.
SUPPLEMENTARY INFORMATION: Under section 409(b)(5) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 348(b)(5)), we are giving notice that
we have filed a food additive petition (FAP 5M4841), submitted by
Monterey Mushrooms, LLC, 260 Westgate Dr., Watsonville, CA 95076. The
petition proposes to amend the food additive regulations in Sec.
172.382 (21 CFR 172.382 Vitamin D2 mushroom powder) to
provide for production of the additive by exposing sliced or diced
edible cultivars of Agaricus bisporus to ultraviolet light.
The petitioner has claimed that this action is categorically
excluded from the requirement to prepare an environmental assessment or
an environmental impact statement under 21 CFR 25.32(k) because the
substance is intended to remain in food through ingestion by consumers
and is not intended to replace macronutrients in food. In addition, the
petitioner has stated that, to their knowledge, no extraordinary
circumstances exist. If FDA determines a categorical exclusion applies,
neither an environmental assessment nor an environmental impact
statement is required. If FDA determines a categorical exclusion does
not apply, we will request an environmental assessment and make it
available for public inspection.
Dated: December 13, 2024.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2024-30362 Filed 12-23-24; 8:45 am]
BILLING CODE 4164-01-P